Download PDF
Thromb Haemost 1975; 33(03): 493-500
DOI: 10.1055/s-0038-1647842
Original Article
Schattauer GmbH

Platelet and Fibrinogen Survival with 75Se Selenomethionine in Acute Infectious Hepatitis

S Musumeci
1   Department of Paediatrics, University of Catania, Catania, Italy
,
A D’Agata
1   Department of Paediatrics, University of Catania, Catania, Italy
,
M. G Panebianco
1   Department of Paediatrics, University of Catania, Catania, Italy
,
S LI Volti
1   Department of Paediatrics, University of Catania, Catania, Italy
› Author Affiliations
Further Information

Publication History

Received 17 September 1974

Accepted 20 January 1975

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

Summary

Simultaneous platelet and fibrinogen survival with 75Se selenomethionine was determined in eight patients with acute infectious hepatitis of intermediate severity. Fibrinogen survival alone was estimated in another nine patients, seven of whom were receiving heparin treatment. Platelet survival was found to be normal (7–9 days) in seven of the 8 patients ; it was reduced (4.6 days) only in one patient, who was also affected by measles. Fibrinogen survival was markedly reduced (1–3.7 days) and fibrinogen turnover sharply increased (0.59–2.80 mg/ml/day) in all but one patient, who had thalassaemia major, with normal fibrinogen survival and fibrinogen turnover. Heparin treatment did not affect either platelet survival or fibrinogen turnover. In all patients the coagulation defect was mild and no sign of disseminated intravascular coagulation or of increased fibrinolytic activity could be demonstrated by routine tests. These results are consistent with the hypothesis that in acute infectious hepatitis the decreased survival and increased turnover of fibrinogen might be due to a pathological pathway of defibrination independent of thrombin or plasmin.

 

  • References

  • 1 Awwad H. K, Potchen E. J, Adelstein S. J, Dealy Jr. J. B. 75Seselenomethionine incorporation into human plasma proteins and erythrocytes. Metabolism 1966; 15: 626
    CrossrefPubMedGoogle Scholar
  • 2 Brecher G, Cronkite E. P. Morphology and enumeration of human blood platelets. Journal of Applied Physiology 1950; 3: 365
    CrossrefPubMedGoogle Scholar
  • 3 Brodsky I, Siegel N. H, Kahan S. B, Ross E. M, Petrov G. Simultaneous fibrinogen and platelet survival with 75Seselenomethionine in man. British Journal of Haematology 1970; 18: 341
    CrossrefPubMedGoogle Scholar
  • 4 Budtz-Olsen O. E. Clot Retraction. Oxford: Blackwell Scientific Publications; 1963
    Google Scholar
  • 5 Cohen C, Revel J. P, Kuceea J. Paracrystalline forms of fibrinogen. Science 1951; 141: 436
    PubMedGoogle Scholar
  • 6 Dacie J. V, Lewis S. M. Practical Haematology. 4th edn. London: J. & A. Churchill Ltd; 1968
    Google Scholar
  • 7 Dechavanne M, Bouletreau P, Petit P. Hepatite virale grave. Coagulation intravasculare et fibrinolyse. Etude radio-isotopique de la duree de vie de plaquettes et du fibrinogene. La Presse Médicale 1971; 79: 2485
    PubMedGoogle Scholar
  • 8 Gallus A. S, Lucas C. R, Hirsh J. Coagulation studies in patients with acute infectious hepatitis. British Journal of Haematology 1972; 22: 761
    CrossrefPubMedGoogle Scholar
  • 9 Godal H. C. The interaction of protamine with human fibrinogen and the significance of this interaction for the coagulation of fibrinogen. Scandinavian Journal Laboratory and Clinical Investigation 1960; 12: 433
    PubMedGoogle Scholar
  • 10 Godal H. C, Abildgaard U. Gelation of soluble fibrin in plasma by ethanol. Scandinavian Journal of Haematology 1966; 3: 342
    PubMedGoogle Scholar
  • 11 Hawiger J, Collins R. D, Horn R. G. Precipitation of soluble fibrin monomer complexes by lysosomal protein fraction of polymorphonuclear leukocytes. Proceedings of the Society for Experimental Biology and Medicine 1969; 131: 349
    PubMedGoogle Scholar
  • 12 Von Kaulla K. N. Chemistry of Thrombolysis: Human Fibrinolytic Enzymes . Springfield: Thomas; 1963: III
    Google Scholar
  • 13 Lee S. L, White P. D. Clinical study of the coagulation time of blood. American Journal of the Medical Sciences 1913; 145: 495
    CrossrefPubMedGoogle Scholar
  • 14 Lowry O. H, Rosebrough N. J, Far A. L, Randall R. J. Protein measurement with the Polin fenol reagent. Journal Biological Chemestry 1951; 193: 265
    PubMedGoogle Scholar
  • 15 Merskey C. Defibrination syndrome or …? (Editorial). Blood 1973; 41: 599
    PubMedGoogle Scholar
  • 16 Musumeci S, D’Agata A, DI Gregorio L. La sopravvivenza delle piastrine e del fibrinogeno nella sindrome di Wiskott Aldrich. La Pediatria 1973; 81: 490
    PubMedGoogle Scholar
  • 17 Najean Y, Ardaillou N. The use of 75Seselenomethionine for the in vivo study of platelet kinetics. Scandinavian Journal of Haematology 1969; 6: 395
    PubMedGoogle Scholar
  • 18 Ratnoff O. D, Menzie C. New method for the determination of fibrinogen in small samples of plasma. The Journal of Laboratory and Clinical Medicine 1951; 37: 316
    PubMedGoogle Scholar
  • 19 Rizza C. R. The clinical feature of clotting factor deficiencies. In Rosemary Biggs. (ed.) Human Blood Coagulation, Haemostasis and Thrombosis . Oxford: Blackwell Scientific Publication; 1972
    Google Scholar
  • 20 Seligsohn U, Rapaport S. I, Kuefler P. R. Extra-adrenal effect of ACTH on fibrinogen synthesis. American Journal of Physiology 1973; 224: 1172
    PubMedGoogle Scholar
  • 21 Stewart G. J, Niewiarowski S. Aggregation of fibrinogen and its degradation products by basic proteins. An electron microscope study. Thrombosis et Diathesis Haemorrhagica 1971; 25: 566
    PubMedGoogle Scholar
  • 22 Terada H, Baldini M, Ebbe S, Madoff M. A. Interaction of influensa virus with blood platelets. Blood 1966; 28: 213
    CrossrefPubMedGoogle Scholar